The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial.
Robert J FoxTommi TervonenAndrea Phillips-BeyerTatiana SidorenkoNeli BoyanovaAnne BrooksBrian HennessyCarol JamiesonBennett LevitanPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2022)
MS patients would accept 0.06 more relapses/year to change their fatigue by a similar magnitude as the between-treatment difference observed in the OPTIMUM trial.
Keyphrases
- multiple sclerosis
- study protocol
- end stage renal disease
- clinical trial
- phase iii
- ejection fraction
- newly diagnosed
- phase ii
- mass spectrometry
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- electronic health record
- ms ms
- case report
- big data
- patient reported outcomes
- machine learning
- artificial intelligence
- open label
- depressive symptoms
- combination therapy
- free survival
- patient reported
- placebo controlled